Beyond oral and intravenous diuretics: intranasal bumetanide for heart failure decongestion

Heart failure (HF) remains a major cause of morbidity, hospitalization, and healthcare expenditure, with acute decompensated HF accounting for more than 1.2 million hospital admissions annually in the United States. Intravenous loop diuretics remain the standard for acute decongestion; however, their reliance on venous access, monitoring, and hospital infrastructure limits outpatient use and contributes to recurrent healthcare utilization. These limitations have driven interest in alternative strategies capable of achieving effective decongestion in ambulatory settings. Intranasal bumetanide has emerged as a potential option by bypassing the gastrointestinal tract, where intestinal edema, impaired splanchnic perfusion, and gastrointestinal dysmotility during HF decompensation may lead to unreliable oral absorption. In a randomized three-way crossover trial involving 68 healthy participants, intranasal bumetanide demonstrated systemic exposure comparable to oral and intravenous administration, with similar peak concentrations and area under the curve. It also showed reduced pharmacokinetic variability compared with oral therapy (~27% vs >40% intrasubject variability) and more rapid absorption, with time to maximum concentration of approximately 1.0 hours (intranasal) vs 1.5 hours (oral), suggesting a more predictable onset of diuretic effect. Pharmacodynamic responses, including urine output and urinary sodium excretion at 2 and 24 hours, were comparable across all routes, with a favorable safety profile and minimal adverse effects. Despite these findings, important limitations remain, particularly the absence of data in patients with HF, uncertainty regarding absorption during acute congestion, and concerns related to unsupervised outpatient administration. Further clinical studies are required to define the efficacy, safety, and clinical role of intranasal bumetanide in HF management.